£1.5M
The Swansea-based diagnostics firm secured £1.5m from a syndicate of investors to support product development and clinical trials.
C
CanSense
CanSense develops an early-stage blood test for bowel cancer using laser spectroscopy and artificial intelligence.
Swansea, UK
£1.5MTotal raised
CanSense has developed a blood test combining laser spectroscopy and artificial intelligence to diagnose bowel cancer early. The method offers a faster, less invasive alternative to traditional colonoscopies.
Categories
Team
PD
Peter Dunstan
Professor
DH
Dean Harris
Professor
CJ
Cerys Jenkins
Dr
AB
Adam Bryant
CEO